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The aim of this study was to evaluate the applicability of fluorine-19 magnetic resonance spectroscopy (
19F MRS) for monitoring in
vivo the conversion of 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU) after using an attenuated Salmonella Typhimurium strain
recombinant to provide cytosine deaminase (TAPET-CD). The
19F MRS measurements were done on mice bearing the human colon
tumour xenograft (HCT116). The intratumoural conversion is greater when TAPET-CD/5-FC is delivered intratumourally (i.tu.) than
when TAPET-CD is delivered intravenously (i.v.) and 5-FC intraperitoneally (i.p.). Repeat measurements of the same tumour also
yielded important information on the tumour colonization by TAPET-CD through the correlated 5-FC to 5-FU conversion efficacy.
The in vivo MRS spectra were confirmed by in vitro
19F MRS of perchloric acid extracts of the tumour tissue. No 5-FU metabolites
were detectable in vivo in the tumours. However, the in vitro measurements revealed, besides 5-FC and 5-FU, the presence of small
amounts of catabolites. Finally, spectra obtained in vitro from liver extracts of tumour-bearing mice treated i.tu. with TAPET-CD/5-FC
showed no 5-FU and only little amounts of catabolites. Our data illustrate most importantly the potential of
19F MRS to monitor
biologically-based treatments involving cytosine deaminase.
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New developments for cancer treatment are allowing individua-
lized and biologically-based therapies. As part of these develop-
ments one needs to accurately define both physical and biological
characteristics of tumours, and to monitor the efficacy of
treatment on an individual basis. Techniques such as computed
tomography (CT) or magnetic resonance imaging (MRI) have been
shown extremely useful in defining the physical limits of the
tumour. Progress has also been made with regards to the
evaluation of biological parameters of the tumour microenviron-
ment (eg, hypoxia) and dynamic monitoring of therapy-induced
changes (eg, 5-fluorouracil (5-FU) chemotherapy). Yet, further
progress is of crucial importance for the evaluation of new
biologically-based therapies that may be more tumour specific
than traditional therapies, and which necessitate a stringent
individualized follow-up. Technologies that are being explored in
this context are positron emission tomography (PET) and
magnetic resonance spectroscopy (MRS). The application of
biological imaging methodologies is essentially non-invasive, and
thus biopsies before and during the treatment do not need to be
taken, leaving the tumour microenvironment undisturbed.
Furthermore, these methods allow potential screening of tumours
at many sites of the body and enable the direct comparison with
normal tissues.
The use of MRS to non-invasively assess biochemical properties
of tumours (eg, pH and lactate), and to evaluate concentrations
and pharmacology of fluorinated chemotherapeutics has been
reported. Compounds such as 5-FU lend themselves to this
methodology because fluorine-19 (
19F) has high sensitivity (83%
relative to
1H), and because only negligible amounts of
19F are
normally present in the body. 5-FU is a well-known chemother-
apeutic agent, and has been evaluated along with the various
metabolites. Although 5-FU measurements are often done in
plasma samples, studies indicate that plasma levels do not reflect
the intratumoural activity of 5-FU (Finan et al, 1987; Hull et al,
1988; Findlay et al, 1996). Using
19F MRS, 5-FU and metabolites
could be detected directly in the tumour and in the liver, in both
preclinical animal investigations as well as in patient studies of
systemically delivered 5-FU (Stevens et al, 1984; Wolf et al, 1990;
reviewed in Martino et al, 2000). Studies in animals and patients
suggest that the trapping of 5-FU and the amount of anabolites in
the tumour correlate with response and may yield prognostic
information on treatment outcome (McSheehy et al, 1989, 1992;
Wolf et al, 1990, 1998; Findlay et al, 1993; Presant et al, 1994;
Schlemmer et al, 1999). Furthermore, in MRS the area of the
spectral peak is proportional to the concentration of the
corresponding metabolite (absolute concentrations require cali-
bration). Although PET is more sensitive than MRS, the former
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stechnique lacks the capacity to distinguish in vivo between the
prodrug, the drug and the different metabolites.
Others and we have been investigating a new biologically-based
cancer therapy involving the cytosine deaminase (CDase) enzyme/
prodrug system. The non-mammalian enzyme CDase converts the
non-toxic 5-FC to the cytostatic drug (5-FU). Previous results
showed that recombinant bacteria can be used as a delivery vector
to transfer CDase selectively to the compromised intratumoural
microenvironment. The tumour-selective applicability of this
strategy has recently been demonstrated in vitro and in vivo with
non-pathogenic clostridia (Minton et al, 1995; Fox et al, 1996;
Theys et al, 2001) and attenuated Salmonella Typhimurium
(msbB
 ,purI
  strain; Vion Pharmaceuticals Inc.) (Low et al,
1999; Lee et al, 2001; King et al, 2002; Mei et al, 2002). Since such
bacteria-based vectors are tumour selective, the enzyme/prodrug
system may provide maximal tumour dosing with prolonged drug
presence and circumvent treatment-limiting side effects (reviewed
by Aghi et al, 2000).
MRS has already been shown to be able to detect conversion of
5-FC to 5-FU in tumours in which cells have been engineered to
express CDase or by using a monoclonal tumour targeting
antibody-CDase conjugate (Aboagye et al, 1998; Stegman et al,
1999).
The objective of the present study is to demonstrate the
applicability of
19F MRS to assess non-invasively biological
therapies. Specifically,
19F MRS is applied in a situation in which
the expression of the therapeutic gene, and thus the conversion
efficacy, is expected to be dependent on the microenvironment and
biological characteristics of the tumour. Attenuated S. Typhimur-
ium engineered to express CDase (TAPET-CD) were investigated
in a mouse-xenografted human tumour model.
Our results show that the selective intratumoural production of
5-FU by a biologically-based therapy such as the TAPET-CD/5-FC
strategy, can be monitored using
19F MRS.
MATERIALS AND METHODS
In vivo tumour model
HCT116 human colon tumour was xenografted subcutaneous (s.c.)
in nu/nu mice using 1 10
6 cells per 100ml. The cells were
inoculated into the lower flank. At the time of TAPET-CD injection
and of
19F MRS, the tumour volumes were between 300mm
3 and
2000mm
3 (tumour volumes were measured with Vernier calipers
in three orthogonal directions and calculated with the formula
L H W PI/6).
All animal experiments were approved by the Animal Ethics
Committee of the University ‘KU Leuven’, and procedures were
according to the guidelines defined by the UKCCCR (Workman
et al, 1998).
Bacterial strain and non-MRS evaluation
The bacteria used were attenuated Salmonella Typhimurium,
recombinant for cytosine deaminase (coded VNP20047, provided
for research by VION Pharm. Inc. New Haven CT 06511, and
hereafter referred to as TAPET-CD). The bacteria were grown in
liquid modified LB medium at 371C to a given number that was
determined by OD600nm measurements (see details in Mei et al,
2002).
Intratumoural (i.tu.) injections of 1 10
8 to 3 10
8 bacteria per
100ml were given in two directions which, considering the size of
the tumour and the insertion depth of the needle, were mainly
central. The TAPET-CD were injected at a very slow rate to avoid
leakage of the suspension. The intravenous injections (tail vein)
consisted of 5 10
5 to 1 10
6 bacteria. The time of bacterial
injection was considered day 0.
To evaluate the intratumoural colonization of the TAPET-CD
(n¼7), 1g samples were taken aseptically and randomly from
tumours not used for in vitro MRS. The tissue samples were
homogenized and suspended in 1ml of saline. Bacterial coloniza-
tion was subsequently quantified by serial dilution series in
modified LB broth. All samples were kept at 371C for 24h, at which
time the colony-forming units (cfu) per gram of tissue were
determined.
The preparation of the bacterial lysates for in vitro analysis of
CDase activity has been described previously (Theys et al, 2001).
Briefly, aliquots of an exponentially growing TAPET-CD culture
were taken at various optical densities (OD600nm) and centrifuged.
The pellets were washed, sonicated, and the lysates were incubated
at 371C for 24h with a 10mg/ml solution of 5-FC to which Tris HCl
(1 M) was added.
Preparation of tissue perchloric acid extracts (PCA
extracts)
Animals were sacrificed by cervical dislocation and immediately
afterwards the tumour and liver were removed and snap frozen in
liquid nitrogen. The whole tumour or liver was homogenized at
01C in 5ml of cold HClO4 (1 M) per gram tissue. After
homogenization, the sample was incubated on ice for 1h followed
by centrifugation for 15min at 1000g (01C). The supernatant was
decanted and neutralized with KOH (10 M) and KHCO3 (1 M). The
resulting precipitate was discarded following a second centrifuga-
tion. The supernatant was subsequently freeze-dried and the
lyophilizate was dissolved in 0.5ml of a potassium phosphate
buffer (pH 7.0; 1 M).
In vivo and in vitro MRS measurements
In vivo
19F MRS experiments on mice bearing the HCT116 tumour
were performed at 188MHz in a Bruker Biospec (Karlsruhe,
Germany), equipped with a horizontal 4.7 Tesla superconducting
magnet with 30cm bore, using a 10mm transmit-receive surface
coil. Prior to the measurement, the mice were anaesthetized with
intraperitoneally (i.p.) injected sodium pentobarbital (1ml/g body
weight Nembutal
s, Sanofi, Belgium). After administration of the
5-FC (i.tu. 100ml of a 7.5mg/ml solution in saline by one injection
central to the tumour since multiple injections may lead to
multiple peaks (Guerquin-Kern et al, 2000), or i.p. 300mg/kg (ie,
on average 9mg per mouse); SIGMA, Belgium), the mice were
placed on a Perspex plate such that the tumour was positioned
directly above the circular surface coil. Following shimming on the
water proton signal, serial
19F NMR spectra were acquired every
13min during 1 to 2.5h (90 degree pulse of 11ms, total repetition
time (TR)¼0.75s, number of averages (NA)¼1024, spectral
width¼27kHz; acquisition size¼2048 points; no proton decou-
pling). The signals were processed by zerofilling to 4096 points and
exponential multiplication of 6Hz.
Most
19F MRS measurements were performed at day 0 and day 1.
Some animals were also evaluated 1 or 2 weeks after the injection
of TAPET-CD. Before a new injection of 5-FC was given, a
spectrum was first recorded to determine whether there were still
signals present from the previous injection (24h earlier).
The chemical shift of the 5-FU resonance was set to 0p.p.m. The
5-FC signal was observed around 1.2p.p.m. The signal positions
were verified with the i.tu. injection of 5-FC (as before) and 5-FU
(40ml of 50mg/ml Fluroblastine
s, Pharmacia, Belgium) in
tumour-bearing mice treated with TAPET-CD and were also
correlated to the
1H chemical shift of the tumour H2O resonance.
A spherical external reference sample (diameter¼7.5mm, volume
B100ml) containing 4-fluorobenzoic acid (FBA; ACROS, Belgium)
in deuterated water saturated with chromium acetylacetonate
(Cr(acac)3, ACROS, Belgium) was placed B9mm under the coil to
monitor stability of the MRS technique and coil load changes for
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sthe different mice/tumours under evaluation. Absolute concentra-
tions were determined in a separate experiment using a cylindrical
water phantom sample (diameter¼25mm, height¼22mm) con-
taining 1.25mM 5-FC, 2.5mM 5-FU and 10mM NaF.
During the in vivo
19F MRS measurements, the body tempera-
ture of the mice was kept at 361C with the use of warm air
ventilation in the magnet bore.
In vitro analysis of tissue extracts of TAPET-CD/5-FC-treated
animals and in vitro analysis of lysates of TAPET-CD cultures were
performed in a high resolution AMX 360 (8.4 Tesla) spectrometer
(Bruker, Karlsruhe, Germany). Specific settings for the tissue
extracts (278K) were, TR¼2.5s, NA¼3072 or 12288,
1H WALTZ-
16-decoupling during the 1s acquisition; and for the lysates
(295K), TR¼2.5s, NA¼256, no proton decoupling. The tissue
extracts were measured at 278K to exploit the substantially shorter
relaxation time at low temperature (typically a factor three)
(Kamm et al, 1994). Absolute concentrations were determined
using a phantom sample of 5-FU in water (2.8mM, 500ml) with a
coaxial FBA reference sample insert.
Statistics
All results are expressed as averages 7 SEM (with indication of
the number of experiments). Linear regression analysis was
performed where appropriate.
RESULTS
19F MRS to evaluate in vitro the conversion capacity of the
TAPET-CD
In vitro
19F MRS measurements of the conversion of 5-FC to 5-FU
were initially performed in lysates from a series of TAPET-CD
cultures to be used in the experiments. The conversion capacity
increased as a function of TAPET-CD growth status (OD600) and
was optimal when lysates were evaluated at the maximum of the
growth phase (Table 1). This clearly demonstrated the relationship
between the number of viable TAPET-CD and the 5-FU production
(R
2¼0.945) and confirmed the quality of the TAPET-CD stock
used for the in vivo experiments.
In vivo
19F MRS of i.tu. injected TAPET-CD and 5-FC
We subsequently assessed the applicability of
19F MRS to evaluate
in vivo non-invasively the conversion capacity of the TAPET-CD in
the tumour microenvironment. The proof-of-principle was first
demonstrated using HCT116 tumour-bearing mice and local i.tu.
injection of both TAPET-CD and 5-FC. Figure 1 displays an
example of these in vivo
19F MRS measurements performed 1 day
after the TAPET-CD injection, starting immediately after the 5-FC
injection. The 5-FC signal was maximal in the first acquisition that
started within 10min after the 5-FC administration (time needed
for positioning of the animal, for shimming and for acquisition of
a water signal used for calibration of the chemical shift), and
declined slowly during the experimental time of up to 2h. The 5-
FU resonance peak became visible during the first 30min of the
measurement, increasing continuously thereafter as shown with
the serial spectra. Both 5-FC and 5-FU resonances were measured
with adequate spectral resolution. No clear catabolites or
anabolites of 5-FU could be observed during the total experimental
time.
Spectra recorded 24h after the initial 5-FC to 5-FU conversion
measurement, showed complete absence of fluorine signals.
Conversion of 5-FC to 5-FU was however again detectable in these
tumours following a repeat 5-FC i.tu. injection.
Intratumoural conversion of 5-FC to 5-FU was however not
always present at day 1 following the i.tu. TAPET-CD injection. We
hypothesized that this was the result of insufficient bacterial
colonization in these tumours. We therefore repeated the
19F MRS
analysis at a later time point without any additional administration
of TAPET-CD. A representative example of such a measurement is
illustrated in Figure 2A. While very little 5-FC to 5-FU conversion
was detectable at day 1 after the TAPET-CD was locally inoculated,
a substantial conversion was measured during the measurement
on day 7. For both time-points (day 1 and day 7), the
19F MRS
analysis was started within 10min after the i.tu. 5-FC injection.
Figure 2B shows the time course for 5-FC and 5-FU derived from
the top set of spectra in Figure 2A. The time course was similar for
Table 1 Conversion capacity of TAPET-CD as determined by in vitro
19F
MRS on lysates
OD600 5-FC/total F (%) 5-FU/ total F (%)
0.136 86 14
0.548 67 33
1.056 52 48
1.355 13 87
1.880 0 100
At several time-points in the TAPET-CD growth curve, lysates of the TAPET-CD
culture were prepared and incubated with 5-FC for 24h at 371C. The optical density
at 600nm (OD600) is correlated (R
2¼0.945) with the conversion of 5-FC to 5-FU
(relative to the total fluor content¼5-FC+5-FU) as determined with in vitro
19F MRS
(TR¼2.5s; NA¼256; no
1H decoupling; T¼295K).
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20 min 
98 min 
Post inj.
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Figure 1 Serial
19F MRS spectra (13min/spectrum; TR¼0.75s;
NA¼1024; LB¼6Hz; zerofilling to 4096 points) of a tumour in a mouse
treated with the TAPET-CD system at day 0 and i.tu. injected with 5-FC
(100ml of a 7.5mg/ml solution in saline) at day 1.
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Figure 2 (A)
19F MRS study involving a repeat evaluation of a mouse
treated with an i.tu. injection of the TAPET-CD system at day 0 followed
with, in both cases, an i.tu. inoculation of 5-FC (100ml of 7.5mg/ml) 6 to
10min before start of the MRS acquisition (13min/spec): lower group of
spectra obtained at day 1, upper group at day 7. (B) Evolution of the MRS
signal area of 5-FC and 5-FU in the HCT116 tumour at day 7 for the mouse
described in A.
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sall experiments (slopes were  6.170.7A.U./h for 5-FC and
2.070.4 A.U./h for 5-FU, based on linear regression; n¼6). These
data highlight the importance of repeat measurements for
detecting the presence of TAPET-CD conversion efficacy during
the tumour colonization period.
In vivo
19F MRS of i.v. injected TAPET-CD and i.p. 5-FC
The potential clinical applicability of TAPET-CD/5-FC involves not
only i.tu. application but also the systemic delivery of the enzyme/
prodrug system. Intratumoural production of 5-FU following i.v.
injection of TAPET-CD and i.p. injection of 5-FC (300mg/kg) was
measured in vivo in the HCT116 colon tumour (Figure 3A). The 5-
FC concentration in the tumours following i.p. injection was
comparable to the i.tu. administration (3-4mM). A clear conver-
sion of 5-FC to 5-FU was seen with this systemic application of
TAPET-CD/5-FC, although the 5-FU signals were less than with the
i.tu. delivery route (compare Figure 1 and Figure 3A).
Because of the reduced 5-FU signal, the conversion quality was
further analysed and confirmed with in vitro high resolution
19F
MRS (8.4 Tesla) of extract preparations from these tumours.
Intratumoural concentrations of 5-FU were about 0.570.2mM
(n¼6) for the i.tu. and 0.1570.07mM (n¼7) for the systemically
TAPET-CD plus 5-FC treated tumours respectively. A representa-
tive example of this analysis (Figure 3B) illustrates the efficacy of
the TAPET-CD/5-FC conversion to 5-FU in this i.v./i.p. adminis-
tration modality.
Within the total in vivo experimental time, no metabolic activity
was observed in the tumours, ie, the concentrations of the
catabolites and anabolites of 5-FU were below the detection
threshold of the in vivo
19F MRS. Using the much more sensitive in
vitro MRS on tumour extracts, we observed a small catabolite
signal around  17p.p.m. (i.tu. 0.170.1mM (n¼4), i.p.
0.02570.025mM (n¼5)) and in some cases also a very small
anabolite signal between 3.5 and 5.5p.p.m. (B0.015mM) (an
example is shown in Figure 4).
Those tumours, which were not further investigated with in vitro
MRS, were analysed for bacterial colonization. Levels of
5 10
872 10
8cfu per gram tissue were found.
In vitro
19F MRS of liver PCA extracts of mice treated with
TAPET-CD/5-FC
It is obviously important to evaluate normal tissue in parallel with
tumour tissue, as both ultimately determine the therapeutic
window of treatment. Besides the perchloric acid extracts of
tumours, also extracts of snap-frozen livers were thus analysed
with in vitro
19F MRS. In all cases where conversion to 5-FU was
detected in the tumour (both after 5-FC i.p. or i.tu.), small
catabolite signals of a-fluoroureido-b-propionic acid (FUPA) at
 17.3p.p.m. and a-fluoro-b-alanine (FBAL) at  18.6p.p.m. were
observed in the liver extracts (Figure 5). Although the conversion
to 5-FU that was observed in the tumour after the i.tu. TAPET-CD/
5-FC application was stronger than after the systemic route, the
catabolite levels in the liver were similar for the i.tu. method
(0.0570.04mM (n¼3)) and the systemic administration
(0.0970.02mM (n¼6)).
DISCUSSION
In the present
19F MRS study we demonstrate the non-invasive
detection of the dynamic production of 5-FU from 5-FC in the
human HCT116 colon tumour xenograft following the use of
cytosine deaminase- (CDase-) recombinant S. Typhimurium
(TAPET-CD). The results show intratumoural conversion of 5-FC
to 5-FU within 30min which proceeded throughout the MRS
measurement time extending up to 1.5–2h after the 5-FC
injection. This suggests that continued intratumoural production
of 5-FU is greater than the diffusion of 5-FU from the tumour into
−25 −20 −15 −10 −5 0 5 10
Chemical shift (ppm)
-2 -1 0 1 2 3 4 5
Chemical shift (ppm)
5-FC
5-FU
5-FC
5-FU A
B
Figure 3 (A) In vivo
19F MRS spectrum obtained after 2 weeks (20min/
spectrum; TR¼0.75s; NS¼1536) of a mouse treated with an i.v. injection
of the TAPET-CD system (day 0) followed with an i.p. 5-FC injection
(300mg/kg). Spectrum obtained 2.5h after 5-FC inoculation. (B) In vitro
19F
MRS spectra of the perchloric acid extract of the whole tumour from the
mouse in Figure 3A, snap-frozen immediately after the in vivo evaluation
(TR¼2.5s; NA¼12228;
1H decoupling).
−2 −1 0 1 2 3 4 5
Chemical shift (ppm)
−19 −18 −17 −16
3 4 5 6
×10 
×10  5-FC
5-FU
FUPA
Figure 4 In vitro
19F MRS spectrum (TR¼2.5s; NA¼12228;
1H
WALTZ-16 decoupling) of the perchloric acid extract of the whole tumour
shown in Figure 2, snap-frozen 2h 47min after the in vivo evaluation. A
large conversion of 5-FC to 5-FU is visible in agreement with the large delay
between in vivo
19F MRS and span freezing. Only small anabolite
(B4p.p.m.) and catabolite signals (B 17p.p.m.) are observed.
−19 −18 −17 −16 −2 −1 0 1 2 3 4 5
Chemical shift (ppm)
×20
5-FC
FUPA 
FBAL
×20 ×20 A
B
Figure 5 In vitro
19F MRS spectra (TR¼2.5s; NA¼12228;
1H WALTZ-
16 decoupling) of the perchloric acid extract of the whole liver: (A) The
liver of a mouse (Figure 2) treated i.tu. with TAPET-CD on day 0 and
injected i.tu. with 5-FC on day 1 and 7, snap-frozen 2h 50min after the in
vivo evaluation (ie, about 4h after the 5-FC administration). (B) The liver of
a mouse treated i.v. with TAPET-CD (day 0) and i.p. with 5-FC (day 14),
snap-frozen immediately after the in vivo evaluation (ie, about 2h after the
5-FC administration).
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sthe systemic circulation of the animal. The high resolution in vitro
19F MRS analysis of the snap-frozen whole tumours confirmed the
in vivo results. At the end of the MRS measurement, the i.tu. 5-FU
signal corresponded to about 0.570.2mM.
With investigations involving the injection of i.v. TAPET-CD
and i.p. 5-FC, we measured an intratumoural 5-FU concentration
of about 0.1570.07mM two hours post 5-FC injection. Although
this is more than three times less than what is found after an i.tu.
injection (0.570.2mM), this still represents about 20mg/ml 5-FU
(based on 300mg/kg 5-FC given i.p. in the present experiments).
Lambin and colleagues discussed the potential of the bacteria-
based CDase/5-FC strategy to improve the therapeutic outcome
from the combination with radiotherapy (Lambin et al, 2000).
Based on published data they estimated that an intratumoural
production of 0.6–0.9mg/ml of 5-FU would lead to a radio-
sensitization factor of 1.1–1.2 when combined with standard 2Gy
radiotherapy schedule. Therefore the 5-FU levels obtained with the
present bacterial CDase/5-FC system should lead to a highly
significant radiosensitization.
The in vivo
19F MRS indicated the lack of 5-FU metabolites in
tumours. Yet, the in vitro measurements of PCA extracts of the
same tumours enabled the detection of small amounts of
catabolites and sometimes anabolites. The formation of fluoronu-
cleosides and fluoronucleotides from 5-FU is known to be a slow
process and may also depend on the type of tumour under
investigation. The concentration of the free anabolites could on the
other hand remain below the sensitivity of the
19F MRS, although
cytostatic activity is present, a possibility discussed by McSheehy
and Griffiths (1989).
We investigated in vitro the extracts of several snap-frozen livers
from TAPET-CD/5-FC treated tumour-bearing mice that presented
with a strong intratumoural 5-FU signal. This
19F MRS analysis
revealed the absence of 5-FU and only small amounts of catabolites
in the liver, at least up to 2h after the in vivo measurements. Our
results agree with the observations made by King et al, (2002)
using high-performance liquid chromatography. The difference
between the small catabolite levels in our study and the large levels
usually found with conventional 5-FU chemotherapy, is obvious
for two reasons: (1) it is expected that the ‘leakage’ of 5-FU from
the tumour microenvironment into the systemic circulation is
poor (eg, indirectly shown by Wallace et al, 1994), and (2) this type
of conversion occurs mainly in the liver and little FBAL enters the
systemic circulation (discussed by eg, Prior et al, 1990).
The difference in spectral quality for mice treated with i.p. versus
i.tu. 5-FC injection is, besides the conversion quality, also partially
related to the broader linewidths that are observed after an i.p.
injection. This increases the overlap of the 5-FC peak with the 5-FU
peak and decreases the signal-to-noise ratio. For this reason the 5-
FU signal was most clearly observed when the 5-FC signal had
significantly decreased (about 2.5h after injection).
The
19F MRS measurements allowed us to gain a better
understanding of some of the characteristics of the TAPET-CD/
5-FC treatment strategy. First, a period ranging from 1 to 7
days seems necessary for the bacteria to establish and proli-
ferate selectively in the tumours and express sufficient levels of
CDase. This agrees with our previous work using the TAPET-CD/
5-FC, in which the rat rhabdomyosarcoma tumour model was
used (Mei et al, 2002). Using in vitro analysis of bacterial
lysates, we also clearly demonstrated the positive correlation
between the number of TAPET-CD and the amount of 5-FC that
is converted to 5-FU for a given incubation period. Second,
the TAPET-CD persist in the tumours without the need for a
repeat injection, similar to the findings of King et al, (2002)
and Mei et al, (2002). Indeed, in the present study, the production
of 5-FU after the i.p. 5-FC administration was measurable even
at 14 days after the injection of the bacteria. Third, intertumoural
variation in the production of 5-FU in vivo was present. This
can likely not be explained on the basis of differences in TAPET-
CD colonization of the tumours. Indeed, the analysis for intra-
tumoural presence revealed colonization levels of 5 10
87
2 10
8cfu per gram of tumour tissue. However, tumours are
inherently morphological heterogeneous, a fact which may
partly explain differences of drug levels (as discussed by Kamm
et al, 1996).
CONCLUSION
The present results are to our knowledge the first demonstration of
the applicability of
19F MRS to monitor in vivo the intratumoural
activity of CDase-recombinant bacteria. This suggests that MRS
may be useful for monitoring therapy with TAPET-CD/5-FC since
it allows repetitive examinations without the need to interfere with
the microenvironment. The use of non-pathogenic strains of
bacteria to transfer effector genes and therapeutic proteins
selectively to the tumour microenvironment is being intensively
investigated (Minton et al, 1995; Zheng et al, 2000; Theys et al,
2001; King et al, 2002; Liu et al, 2002). Based on the promising
preclinical in vitro and in vivo data, including the positive safety
profile, the application of the attenuated Salmonella strain (both
i.tu. and i.v. administration) is being tested in clinical phase I
studies (Cunningham and Nemunaitis, 2001; Toso et al, 2002).
From the perspective of the broader application of the novel anti-
cancer treatment (eg, optimisation of protocol, combining with
radiotherapy or chemotherapy), the non-invasive MR methodol-
ogy thus offers a significant advance for individual guidance and
longitudinal monitoring of treatment.
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